00874 BAIYUNSHAN PH
- 17.340
- +0.100+0.58%
BAIYUNSHAN PH News
Baiyunshan (00874.HK) treats acute pharyngitis with generic drugs that have passed the national drug regulatory authority's generic drug consistency evaluation.
Baiyunshan (00874.HK) announced that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Group Baiyunshan Pharmaceutical General Factory, recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration, and the "Achimycin Capsule" has passed the generic drug quality and efficacy consistency evaluation. It is introduced that "Achimycin" is mainly used to treat acute pharyngitis and acute tonsillitis caused by Streptococcus pyogenes; sinusitis, otitis media, acute bronchitis, and acute exacerbation of chronic bronchitis caused by sensitive bacteria; pneumonia caused by Streptococcus pneumoniae, influenza bacillus, and pneumonia caused by chlamydia and non-multidrug-resistant mycoplasma.
Baiyunshan (00874): Baiyunshan Pharmaceutical General Factory's azithromycin capsules have passed the generic drug consistency evaluation.
Baiyunshan (00874) announced that its subsidiary Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. recently...
HK stock news | Baiyunshan (00874) fell more than 3%, second quarter performance under pressure, and Morgan Stanley lowered the company's profit expectations and target price.
Baiyunshan (00874) fell more than 3%, as of the time of writing, it fell 3.02%, to HK$16.7, with a turnover of HK$2.9731 million.
Daiwa: maintains the 'in line with the market' rating for baiyunshan (00874), with a target price lowered to 21.7 Hong Kong dollars.
Deutsche Bank has lowered its profit expectations for Baiyunshan from 2024 to 2030 by 3%-11%.
Guangzhou Baiyunshan Pharmaceutical Gets License to Expand Unit's Drug Production License
baiyunshan (00874) subsidiary Mingxing Pharmaceutical has received the Pharmaceutical Production License issued by the Drug Supervision and Administration Bureau of Guangdong Province.
Baiyunshan (00874) issued an announcement. Recently, the company's wholly-owned subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. (referred to as...
Hong Kong stock announcement | Two national-level specialized, special and new "little giant" enterprises added to circ
Wuxi AppTec (02359) plans to repurchase 1 billion yuan of A shares to further maintain the company's value and shareholder rights; Baiyunshan (00874): glyceryl trinitrate injection has passed the generic drug quality and efficacy consistency evaluation.
Baiyunshan Pharma Gets China Supplemental Drug Nod for Nitroglycerin Injection for Heart Problems
Express News | Baiyun Mountain: Nitroglycerin injection passed the consistency evaluation
Baiyunshan ph (00874) received the "Pharmaceutical Production License" approved and issued by the Guangdong Pharmaceutical Supervision Administration.
Baiyunshan (00874) announced that its wholly-owned subsidiary, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. (also known as...
Baiyunshan Pharmaceutical's Executive Director Resigns Amid Ongoing Investigation
Baiyunshan (600332): Performance meets expectations, with commercial sector revenue maintaining a good growth.
1H24 performance meets our expectations The company announced its performance for the first half of 2024: revenue of 41.04 billion Chinese yuan, a year-on-year increase of 2.68%; net income attributable to shareholders of 2.55 billion Chinese yuan, a year-on-year decrease of 9.31%; dedu
A-share abnormal volatility | Mid-term revenue growth without profit, Baiyunshan fell nearly 8% in the afternoon, hitting a seven-month low in stock price.
On September 2nd, Baiyunshan (600332.SH) fell by nearly 8% to a new 7-month low of 26.52 yuan, with a significantly increased turnover of 0.712 billion yuan and a total market value of 43.1 billion yuan. The company's revenue for the first half of the year was 41.043 billion yuan, a year-on-year increase of 2.68%; net income was 2.668 billion yuan, a year-on-year decrease of 8.68%; operating cash flow was -2.037 billion yuan, a year-on-year decrease of 174.97%. It is worth noting that the accounts receivable/revenue ratio for the past three semi-annual reports was 38.93%, 40.29%, and 40.74% respectively.
Hong Kong stocks have changed | Baiyunshan (00874) is now down more than 5%, and the net income attributable to the mother has decreased by 9.31% year-on-year. Former Chairman Li Chuyuan is under investigation.
baiyunshan (00874) fell more than 5%, as of the time of writing, it fell by 5.45%, to 18.38 Hong Kong dollars, with a turnover of 29.2393 million Hong Kong dollars.
Performance: Baiyunshan (00874.HK) half-year net profit of 2.55 billion RMB, a decrease of 9.3%. Dividend of 4 RMB per 10 shares.
Baiyunshan (00874.HK) announced its interim performance as of the end of June this year, with revenue of 41.043 billion RMB (Same below), an annual increase of 2.7%. Net profit of 2.55 billion yuan, a year-on-year decrease of 9.3%; earnings per share of 1.568 yuan. Proposing a dividend of 4 yuan per 10 shares.
Express News | Baiyunshan ph: Director Zhang Chunbo resigned for personal reasons.
Full text of the 2024 semi-annual report of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
Summary of the 2024 semi-annual report of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
Baiyunshan (00874) plans to distribute a cash dividend of 0.4 yuan per share.
Baiyunshan (00874) announced that the company plans to distribute a cash dividend of RMB 0.40 per share (including tax).
Baiyunshan (00874) released its interim performance with a net income attributable to the parent company of 2.55 billion yuan, a decrease of 9.31% year-on-year.
Baiyunshan (00874) has released its interim performance for the six months ended June 30, 2024, during which the group achieved...
Analysis
Price Target
No Data
No Data